This promotional webinar has been organised and funded by Pierre Fabre Ltd and is intended for UK healthcare professionals only.
Tolak (4% fluorouracil) prescribing information and adverse event reporting information can be found here.
UK-TOK-06-25-2500007 June 2025
Online Webinar| 24 July 2025
Empowering frontline teams to spot, support, and streamline referrals
Boost your clinical confidence and skills with our expert-led webinar focused on one of the most common skin conditions seen in primary care.
About the webinar
Actinic keratosis (AK) is a common, yet often challenging, skin condition to diagnose and manage in primary care. Early identification and appropriate treatment are vital to prevent possible progression to skin cancer.
Join us on 24 July for a 1-hour webinar where we will guide you through the key aspects of recognising AK, differentiating it from other skin lesions, and understanding the most up-to-date treatment options – including the effective use of Tolak 4% fluorouracil 5-FU.
You will come away with clear, actionable guidance that can be applied immediately in your clinical practice.

Why this is a must attend
- Improve diagnostic confidence: Gain practical tools and clear visual guidance for accurately identifying AK
- Understand treatment options: Learn when and how to effectively use treatments such as 5-fluorouracil within primary care
- Live Q&A session: Have your questions answered directly by a leading expert
- Complete 1 hour of CPD: Enhance your professional portfolio
- Free and accessible: Participate from any location without cost or travel
Don’t miss this opportunity to enhance your dermatology knowledge and improve patient care
Who should attend this event
UK healthcare professionals working in the following roles:
- GP Partner
- GP Locum/Locum GP
- Salaried GP
- Portfolio GP
- Principal GP
- GP Returner
- Practice Nurse
- Community Nurse
- Nurse Practitioner
- Community Pharmacist
- PCN Pharmacist
- Practice Pharmacist
With a portfolio spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. Its portfolio includes several global brands and franchises, such as Pierre Fabre Dermatologie and Pierre Fabre Oncologie. Pierre Fabre is committed to delivering treatment options to patients with cancer and has been working with oncologists for 30 years to make a difference in their clinical practice.
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation. Pierre Fabre Limited is the UK subsidiary of Pierre Fabre.

